An experimental drug has shown promise in improving some bladder function after spinal cord injury, raising hope of increasing quality of life of affected patients, suggests new research.
The researchers tested the drug -- which is currently available only for research -- to gauge its potential to improve bladder function after spinal cord injury in mice.
After a month-long treatment of the spinal cord injury in mice, the bladder volume decreased significantly to a level close to normal, according to the researcher.
The study, published in The Journal of Clinical Investigation, showed that the experimental drug (LM11A-31) appears to help by blocking the dual activity of pro-nerve growth factor (proNGF) and a receptor called p75.
ProNGF is known to be secreted from the cell after nerve injury, the researcher said.
"There are no approved medications to treat bladder dysfunction brought on by spinal cord injuries, something that is a major concern and diminishes quality of life for these patients," said lead researcher Sung Ok Yoon, Associate Professor, at the Ohio State University.
"This drug appears to help maintain near-normal bladder pressure and less unexpected expulsion of urine in mice," Yoon added.
In humans, spinal cord injuries sever the communication between the bladder and the brain, leading to the loss of the normal ability to urinate at will.
This leads to bladder over-filling, which causes high pressure and bladder enlargement due to thickening of the muscular bladder walls. This can cause urine to return to the kidney, which can lead to kidney infection and disease, the researchers said.
People with spinal cord injury typically rely on a catheter to pass urine, they added.
Eventually a new circuit of nervous-system communication is formed within the spinal cord, and it allows urine to be expelled unexpectedly, causing incontinence, according to Yoon.
Because the experimental drug does not restore normal communication between the bladder and the brain, it is certainly not a cure, Yoon said.
Based on the mouse study, however, patients are likely to experience reduced bladder volume, which would lower the risk of bladder infection and reflux to the kidney, and less incontinence, Yoon added.
--IANS
vc/vd
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
